Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B1 | P14061 | 1/20 | 0.51 |
| ▸ | CA12 | O43570 | 4/20 | 0.50 |
| ▸ | CA1 | P00915 | 4/20 | 0.50 |
| ▸ | CA2 | P00918 | 4/20 | 0.50 |
| ▸ | CA7 | P43166 | 4/20 | 0.50 |
| ▸ | CA9 | Q16790 | 4/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.50 |
| ▸ | PTPN2 | P17706 | 2/20 | 0.50 |
| ▸ | JAK2 | O60674 | 1/20 | 0.50 |
| ▸ | JAK1 | P23458 | 1/20 | 0.50 |
| ▸ | TYK2 | P29597 | 1/20 | 0.50 |
| ▸ | JAK3 | P52333 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | ESR1 | P03372 | 4/20 | 0.47 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31207824 | 1.00 | HSD17B1 (0.51) | HSD17B1CA12CA1CA2CA7 | |
| SCHEMBL1390519 | 0.88 | DYRK1A (0.62) | HSD17B1CA12CA1CA2CA7 | |
| SCHEMBL8250276 | 0.86 | HDAC1 (0.60) | PTPN2MAPTGAAKDM4ETDP1 | |
| SCHEMBL155423 | 0.85 | PTPN2 (0.50) | PTPN2MAPTGAAKDM4ETDP1 | |
| SCHEMBL2238245 | 0.84 | PTPN2 (0.60) | CA12CA1CA2CA7CA9 | |
| SCHEMBL156266 | 0.84 | PTPN2 (0.55) | PTPN2MAPTGAAKDM4ETDP1 | |
| SCHEMBL29559740 | 0.84 | ALOX15 (0.51) | PTPN2MAPTGAAKDM4ETDP1 | |
| SCHEMBL2822973 | 0.84 | PTPN2 (0.49) | CA2PTPN2MAPTGAAKDM4E | |
| SCHEMBL16595447 | 0.84 | ALOX15 (0.51) | PTPN2MAPTGAAKDM4ETDP1 | |
| SCHEMBL2081462 | 0.84 | PTPN2 (0.49) | PTPN2MAPTGAAKDM4ETDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260028334-A1 | N-(3-(BENZO[B]THIOPHENE-2-CARBOXAMIDO)-PHENYL)-2,3-DIHYDROBENZO[B][1,4]DIOXINE-6-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS LACTATE/ATP PRODUCTION INHIBITORS FOR THE TREATMENT OF CANCER | WMT AG (DE) | 2026-01-29 | — | — | US | disclosed |
| EP-4504723-A1 | N-(3-(BENZO[B]THIOPHENE-2-CARBOXAMIDO)-PHENYL)-2,3-DIHYDROBENZO[B][1,4]DIOXINE-6-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS LACTATE/ATP PRODUCTION INHIBITORS FOR THE TREATMENT OF CANCER | WMT AG (DE) | 2025-02-12 | — | — | EP | disclosed |
| CN-118974040-A | N- (3- (benzo [ B ] thiophen-2-amido) -phenyl) -2, 3-dihydrobenzo [ B ] [1,4] dioxin-6-amide derivatives and related compounds as lactic acid/ATP production inhibitors for the treatment of cancer | 威马特股份公司 | 2024-11-15 | — | — | CN | disclosed |
| WO-2023194458-A1 | N-(3-(BENZO[B]THIOPHENE-2-CARBOXAMIDO)-PHENYL)-2,3-DIHYDROBENZO[B][1,4]DIOXINE-6-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS LACTATE/ATP PRODUCTION INHIBITORS FOR THE TREATMENT OF CANCER | WMT AG (DE) | 2023-10-12 | — | — | WO | disclosed |
| WO-2023194458-A1 | N-(3-(BENZO[B]THIOPHENE-2-CARBOXAMIDO)-PHENYL)-2,3-DIHYDROBENZO[B][1,4]DIOXINE-6-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS LACTATE/ATP PRODUCTION INHIBITORS FOR THE TREATMENT OF CANCER | WMT AG (DE) | 2023-10-12 | — | — | WO | disclosed |
| WO-2017179926-A1 | NOVEL BENZOTHIOPHENE DERIVATIVE, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF OR OPTICAL ISOMER THEREOF, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION, CONTAINING SAME AS ACTIVE INGREDIENT, FOR PREVENTING OR TREATING VIRAL DISEASE | 한국화학연구원 | 2017-10-19 | — | — | WO | disclosed |
| US-20170121315-A1 | HETEROBICYCLICALLY SUBSTITUTED 4-OXOBUTANE ACID DERIVATIVES AND USE THEREOF | Bayer Pharma AG (DE) | 2017-05-04 | — | — | US | disclosed |
| US-20170121315-A1 | HETEROBICYCLICALLY SUBSTITUTED 4-OXOBUTANE ACID DERIVATIVES AND USE THEREOF | Bayer Pharma AG (DE) | 2017-05-04 | — | — | US | disclosed |
| US-20170121315-A1 | HETEROBICYCLICALLY SUBSTITUTED 4-OXOBUTANE ACID DERIVATIVES AND USE THEREOF | Bayer Pharma AG (DE) | 2017-05-04 | — | — | US | disclosed |
| WO-2015189117-A1 | HETEROBICYCLICALLY SUBSTITUTED 4-OXOBUTANE ACID DERIVATIVES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-12-17 | — | — | WO | disclosed |
| US-20120010247-A1 | BICYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-01-12 | — | — | US | disclosed |
| US-20120010247-A1 | BICYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-01-12 | — | — | US | disclosed |
| EP-2351743-A1 | BICYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2011-08-03 | — | — | EP | disclosed |
| US-7829585-B2 | Antifungal agent containing pyridine derivative | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-11-09 | — | — | US | disclosed |
| EP-2183237-A1 | BENZOFURAN- AND BENZO[B]THIOPHENE-2-CARBOXYLIC ACID AMIDE DERIVATIVES AND USE THEREOF AS HISTAMINE 3 RECEPTOR MODULATORS | F. Hoffmann-Roche AG (CH) | 2010-05-12 | — | — | EP | disclosed |
| WO-2010050445-A1 | BICYCLIC COMPOUND | 武田薬品工業株式会社 (JP) | 2010-05-06 | — | — | WO | disclosed |
| US-7534788-B2 | Benzofuran and benzothiophene-2-carboxylic acid amide derivatives | HOFFMANN-LA ROCHE INC. (US) | 2009-05-19 | — | — | US | disclosed |
| US-20090062348-A1 | Antifungal Agent Containing Pyridine Derivative | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-03-05 | — | — | US | disclosed |
| WO-2009013195-A1 | BENZOFURAN- AND BENZO[B]THIOPHENE-2-CARBOXYLIC ACID AMIDE DERIVATIVES AND USE THEREOF AS HISTAMINE 3 RECEPTOR MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-01-29 | — | — | WO | disclosed |
| US-20090029976-A1 | BENZOFURAN AND BENZOTHIOPHENE-2-CARBOXYLIC ACID AMIDE DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2009-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010247-A1 | BICYCLIC COMPOUND | ACACA, CPT1B, ACACB | HSD17B1 350/4885CA12 3758/4885CA1 3637/4885 |
| US-20090062348-A1 | Antifungal Agent Containing Pyridine Derivative | ERG28, SQOR, CYP51A1 | HSD17B1 704/4885CA12 2282/4885CA1 4011/4885 |
| US-20090029976-A1 | BENZOFURAN AND BENZOTHIOPHENE-2-CARBOXYLIC ACID AMIDE DERIVATIVES | HCAR2, HCAR1, HRH3 | HSD17B1 1302/4885CA12 2212/4885CA1 1606/4885 |
| US-20170121315-A1 | HETEROBICYCLICALLY SUBSTITUTED 4-OXOBUTANE ACID DERIVATIVES AND USE THEREOF | ABAT, HADHB, CYP11B2 | HSD17B1 352/4885CA12 2843/4885CA1 3612/4885 |
| US-20260028334-A1 | N-(3-(BENZO[B]THIOPHENE-2-CARBOXAMIDO)-PHENYL)-2,3-DIHYDROBENZO[B][1,4]DIOXINE-6-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS LACTATE/ATP PRODUCTION INHIBITORS FOR THE TREATMENT OF CANCER | LDHA, LDHB, SLC6A1 | HSD17B1 883/4885CA12 1100/4885CA1 539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.